Enterprise Value

361.2M

Cash

995M

Avg Qtr Burn

-52.5M

Short % of Float

13.04%

Insider Ownership

40.86%

Institutional Own.

59.86%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Domvanalimab (FcR-silent TIGIT antibody) Details
Cancer, Gastrointestinal stromal tumors, Gastroesophageal junction tumors, Gastroesophageal adenocarcinomas

Phase 3

Data readout

Phase 3

Initiation

Domvanalimab (FcR-silent TIGIT antibody) Details
Cancer, Non-small cell lung carcinoma

Phase 2/3

Update

Domvanalimab (FcR-silent TIGIT antibody) Details
Cancer, Gastroesophageal junction tumors, Gastric cancer, Esophageal cancer

Phase 2

Update

Phase 2

Update

Phase 2

Update

Phase 1/2

Data readout

Casdatifan/AB521 + zanzalintinib Details
Cancer, Renal cell carcinoma, Solid tumor/s

Phase 1/2

Data readout

Etrumadenant (AB928) + Zimberelimab Details
Metastatic colorectal cancer, Colorectal cancer , Cancer

Phase 1/2

Update

Phase 1

Data readout

Casdatifan/AB521 (HIF-2a inhibitor) Details
Cancer, Renal cell carcinoma, Solid tumor/s

Big Mover™

Susp. Mover™

Phase 1

Data readout

AB801 (AXL inhibitor) Details
Advanced malignancies, Cancer

Phase 1

Initiation

Failed

Discontinued